Last updated: 11 September 2024 at 4:03pm EST

Dr. Mary DiBiase Ph.D. Net Worth




The estimated Net Worth of Mary Di Biase is at least $295 Thousand dollars as of 9 September 2024. Dr Biase owns over 2,642 units of X4 Pharmaceuticals stock worth over $199,486 and over the last 3 years he sold XFOR stock worth over $95,510.

Dr D XFOR stock SEC Form 4 insiders trading

Dr has made over 15 trades of the X4 Pharmaceuticals stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 2,642 units of XFOR stock worth $1,744 on 9 September 2024.

The largest trade he's ever made was selling 67,695 units of X4 Pharmaceuticals stock on 1 November 2023 worth over $49,417. On average, Dr trades about 6,717 units every 47 days since 2021. As of 9 September 2024 he still owns at least 289,110 units of X4 Pharmaceuticals stock.

You can see the complete history of Dr Biase stock trades at the bottom of the page.





Dr. Mary DiBiase Ph.D. biography

Dr. Mary DiBiase Ph.D. is the Chief Operating Officer at X4 Pharmaceuticals.



What's Dr D's mailing address?

Mary's mailing address filed with the SEC is C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON, MA, 02134.

Insiders trading at X4 Pharmaceuticals

Over the last 6 years, insiders at X4 Pharmaceuticals have traded over $2,179,690 worth of X4 Pharmaceuticals stock and bought 25,000 units worth $30,000 . The most active insiders traders include Paula Ragan, Adam S. Mostafa, and Gary Bridger. On average, X4 Pharmaceuticals executives and independent directors trade stock every 19 days with the average trade being worth of $12,232. The most recent stock trade was executed by Mary Di Biase on 9 September 2024, trading 2,642 units of XFOR stock currently worth $1,744.



What does X4 Pharmaceuticals do?

X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.



What does X4 Pharmaceuticals's logo look like?

X4 Pharmaceuticals, Inc. logo

Complete history of Dr Biase stock trades at X4 Pharmaceuticals

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
9 Sep 2024 Mary Di Biase
Chief Operating Officer
Sale 2,642 $0.66 $1,744
9 Sep 2024
289,110
11 Mar 2024 Mary Di Biase
Chief Operating Officer
Sale 15,409 $0.88 $13,560
11 Mar 2024
291,752
12 Feb 2024 Mary Di Biase
Chief Operating Officer
Sale 3,683 $1.01 $3,720
12 Feb 2024
307,161
1 Nov 2023 Mary Di Biase
Chief Operating Officer
Sale 67,695 $0.73 $49,417
1 Nov 2023
310,844
8 Sep 2023 Mary Di Biase
Chief Operating Officer
Sale 2,642 $1.25 $3,303
8 Sep 2023
147,894
30 Jun 2023 Mary Di Biase
Chief Operating Officer
Sale 464 $1.89 $877
30 Jun 2023
150,536
23 Jun 2023 Mary Di Biase
Chief Operating Officer
Sale 857 $1.93 $1,654
23 Jun 2023
151,000
15 Jun 2023 Mary Di Biase
Chief Operating Officer
Sale 857 $2.23 $1,911
15 Jun 2023
151,857
10 Mar 2023 Mary Di Biase
Chief Operating Officer
Sale 18,192 $0.84 $15,281
10 Mar 2023
152,714
13 Feb 2023 Mary Di Biase
Chief Operating Officer
Sale 4,348 $0.93 $4,044
13 Feb 2023
170,906
17 Aug 2022 Mary Di Biase
Chief Operating Officer
Sale 1,713 $1.16 $1,987
17 Aug 2022
177,896
30 Jun 2022 Mary Di Biase
Chief Operating Officer
Sale 1,578 $0.96 $1,515
30 Jun 2022
179,609
24 Jun 2022 Mary Di Biase
Chief Operating Officer
Sale 856 $1.07 $916
24 Jun 2022
181,187
16 Jun 2022 Mary Di Biase
Chief Operating Officer
Sale 856 $1.07 $916
16 Jun 2022
182,043
11 Feb 2022 Mary Di Biase
Chief Operating Officer
Sale 12,545 $1.56 $19,570
11 Feb 2022
77,899


X4 Pharmaceuticals executives and stock owners

X4 Pharmaceuticals executives and other stock owners filed with the SEC include: